Pulmonx Reports Q2 Revenue Decline Amid Sales Force Rebuilding
Pulmonx Corporation (NASDAQ:LUNG) reported second-quarter revenue of $22.8 million for the quarter ended June 30, representing a 5% year-over-year decline and a 6% drop on a constant-currency basis. However, U.S. revenue rose sequentially by 7%, driven by progress in rebuilding its sales force and adding new treating centers. The company reiterated its full-year 2026 revenue guidance of $90 million to $92 million while highlighting improved profitability trends: the net loss narrowed to $10.1 million from $15.2 million, adjusted EBITDA losses fell nearly 40%, and gross margin increased to 78%. Operating expenses declined by 16% year over year. Pulmonx also announced that it has renewed its Chinese registration and expects distributor shipments to resume in early 2027, though significant revenue from this market is not expected until next year. Enrollment continues for the pivotal AeriSeal CONVERT II trial, with completion still anticipated by mid-2026.
Tickers: $LUNG
Topics: guidance net loss improvement revenue sales force rebuilding